Published on Monday January 05, 2026
Smooth Drug Development December 2025 News Release
Monthly News – December 2025
December marked a dynamic end of the year with multiple new contracts and significant regulatory milestones.
New Contracts Secured:
- Data management services for a Phase I Pembrolizumab study
- Medical writing services for a Phase III Linzagolix study
- Organization and conduct of a Phase I antibody–drug conjugate (ADC) trial
- Two bioequivalence studies of Semaglutide
These wins reflect our growing reputation in oncology, women’s health, metabolic disorders, and advanced therapeutics.
Clinical Progress:
- Spinal Muscular Atrophy – Clinical Trial Approval received; project start planned
- Ophthalmology – 25% of enrolled patients completed per protocol
- Phase III Hepatitis – Sites initiated and screening underway
- Phase III Women’s Health – 53 patients randomized
- GLP-1 Receptor Agonist Studies – Clinical approvals secured
- Ovarian Cancer – All sites activated; screening ongoing
Business Development News:
In collaboration with BIOCHINA, Smooth Drug Development will co-host a dedicated session at BIOCHINA 2026 focused on clinical research, pharmaceutical manufacturing, and supply chain opportunities across emerging Belt & Road markets.